BBIO BridgeBio Pharma Inc

Price (delayed)

$48.93

Market cap

$7.33B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.83

Enterprise value

$8.35B

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in ...

Highlights
The gross profit has soared by 65% YoY
BridgeBio Pharma's revenue has soared by 55% YoY
BBIO's net income is down by 43% year-on-year but it is up by 4.7% since the previous quarter
BBIO's EPS is down by 30% year-on-year but it is up by 9% since the previous quarter
BBIO's debt has surged by 191% year-on-year
BridgeBio Pharma's quick ratio has decreased by 31% from the previous quarter and by 26% YoY

Key stats

What are the main financial stats of BBIO
Market
Shares outstanding
149.77M
Market cap
$7.33B
Enterprise value
$8.35B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
114.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
133.04
Earnings
Revenue
$62.74M
EBIT
-$452.8M
EBITDA
-$445.66M
Free cash flow
-$477.37M
Per share
EPS
-$3.83
Free cash flow per share
-$3.25
Book value per share
-$3.11
Revenue per share
$0.43
TBVPS
$7.37
Balance sheet
Total assets
$1.08B
Total liabilities
$1.54B
Debt
$1.4B
Equity
-$464.29M
Working capital
$777.96M
Liquidity
Debt to equity
-3.01
Current ratio
6.9
Quick ratio
6.7
Net debt/EBITDA
-2.28
Margins
EBITDA margin
-710.4%
Gross margin
99.8%
Net margin
-789.5%
Operating margin
-811.3%
Efficiency
Return on assets
-54%
Return on equity
N/A
Return on invested capital
-33.2%
Return on capital employed
-47.7%
Return on sales
-721.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
-0.31%
1 week
7.78%
1 month
-2.99%
1 year
23.06%
YTD
-31.19%
QTD
4.4%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$62.74M
Gross profit
$62.63M
Operating income
-$508.95M
Net income
-$495.27M
Gross margin
99.8%
Net margin
-789.5%
BBIO's operating margin has soared by 87% QoQ and by 9% YoY
BBIO's net margin has surged by 87% since the previous quarter and by 8% year-on-year
The gross profit has soared by 65% YoY
BridgeBio Pharma's revenue has soared by 55% YoY

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
114.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
133.04
BBIO's EPS is down by 30% year-on-year but it is up by 9% since the previous quarter
BBIO's equity is down by 17% since the previous quarter
The stock's price to sales (P/S) is 80% less than its last 4 quarters average of 585.5
BridgeBio Pharma's revenue has soared by 55% YoY

Efficiency

How efficient is BridgeBio Pharma business performance
BBIO's ROS has soared by 87% since the previous quarter and by 10% year-on-year
The ROIC has soared by 50% YoY and by 26% from the previous quarter
The ROA has contracted by 24% YoY but it has grown by 9% from the previous quarter

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 30% smaller than its total liabilities
BBIO's total liabilities has soared by 166% YoY and by 3.8% QoQ
BridgeBio Pharma's quick ratio has decreased by 31% from the previous quarter and by 26% YoY
BBIO's debt has surged by 191% year-on-year
BBIO's equity is down by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.